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GST±D4 pull-down assay
DNA encoding amino acids 595±735 of PA (domain 4) was cloned into pGEX-4T-1
(Pharmacia Biotechnology). GST±D4 was coupled to glutathione sepharose at 4 mg ml-1
GST±D4 according to the manufacturer's instructions (Pharmacia Biotechnology). GST
or GST±D4 coupled to glutathione sepharose was mixed with 2 mg of T7±ATR41±227 and
250 mg of E. coli extract in 250 ml for 1 h at 4 8C. The beads were washed four times with
20 mM Tris-HCl at pH 8.0 and 150 mM NaCl. One-half of the suspension was subjected to
SDS±PAGE, transferred to nitrocellulose, and probed with anti-T7 antibody coupled to
horseradish peroxidase.
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Lethal factor (LF) is a protein (relative molecular mass 90,000)
that is critical in the pathogenesis of anthrax1±3. It is a highly
speci®c protease that cleaves members of the mitogen-activated
protein kinase kinase (MAPKK) family near to their amino
termini, leading to the inhibition of one or more signalling
pathways4±6. Here we describe the crystal structure of LF and its
complex with the N terminus of MAPKK-2. LF comprises four
domains: domain I binds the membrane-translocating compo-
nent of anthrax toxin, the protective antigen (PA); domains II, III
and IV together create a long deep groove that holds the 16-
residue N-terminal tail of MAPKK-2 before cleavage. Domain II
resembles the ADP-ribosylating toxin from Bacillus cereus, but
the active site has been mutated and recruited to augment
substrate recognition. Domain III is inserted into domain II,
and seems to have arisen from a repeated duplication of a
structural element of domain II. Domain IV is distantly related
to the zinc metalloprotease family, and contains the catalytic
centre; it also resembles domain I. The structure thus reveals a
protein that has evolved through a process of gene duplication,
mutation and fusion, into an enzyme with high and unusual
speci®city.
Anthrax poses a signi®cant threat as an agent of biological warfare
and terrorism7. Inhalational anthrax, in which spores of Bacillus
anthracis are inhaled, is almost always fatal, as diagnosis is rarely
possible before the disease has progressed to a point where anti-
biotic treatment is ineffective. The major virulence factors of
B. anthracis are a poly-D-glutamic acid capsule and anthrax
toxin1. Anthrax toxin consists of three distinct proteins that act in
concert: two enzymes, LF and oedema factor (an adenylate
² Present addresses: AstraZeneca, Alderley Park, Maccles®eld SK10 4TG, UK (A.P.); EMBL Grenoble
Outstation, 38042 Grenoble Cedex 9, France (C.P.); Boston University, 36 Cummington Street, Boston,
Massachusetts 02215, USA (J.B.).
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cyclase); and PA. The PA is a four-domain protein8 that binds a host
cell-surface receptor by its carboxy-terminal domain; cleavage of its
N-terminal domain by a furin-like protease allows PA to
form heptamers that bind the toxic enzymes with high af®nity
through homologous N-terminal domains. The complex is endo-
cytosed; acidi®cation of the endosome leads to membrane
insertion of the PA heptamer by forming a 14-stranded b-
barrel8,9, followed by translocation of the toxic enzymes into the
cytosol by an unknown mechanism. The binary combination of PA
and LF (`lethal toxin') is suf®cient to induce rapid death in animals
when given intravenously, and certain metalloprotease inhibitors
block the effects of the toxin in vitro10. Thus, LF is a potential target
for therapeutic agents that would inhibit its catalytic activity or
block its association with PA.
The MAPKK family of proteins are the only known cellular
substrates of LF4±6. Cleavage by LF near to their N termini removes
the docking sequence for the downstream cognate MAP kinase. The
effect of lethal toxin on tumour cells, for example, is to inhibit
tumour growth and angiogenesis, most probably by inhibiting the
MAPKK-1 and MAPKK-2 pathways11. However, the primary cell
type affected in anthrax pathogenesis is the macrophage12,13. Here,
recent evidence shows that low levels of lethal toxin cleave MAPKK-
3, inhibiting release, but not production, of the pro-in¯ammatory
mediators, NO and tumour necrosis factor-a (TNF-a)14. In con-
trast, high levels of lethal toxin lead to lysis of macrophages within a
few hours, by an unknown mechanism12. These observations
suggest that at an early stage in infection, lethal toxin may reduce
(or delay) the immune response, whereas at a late stage in infection,
high titres of the bacterium in the bloodstream trigger macrophage
lysis and the sudden release of high levels of NO and TNF-a. This
may explain the symptoms before death, which resemble those of
septic shock2.
We solved the structure of LF in two crystal forms with very
different packing environments. Nevertheless, differences in tertiary
and quaternary structure are small, and the better diffracting crystal
form has been re®ned to 2.2 AÊ resolution (Figs 1 and 2). The
molecule is 100 AÊ tall and 70 AÊ wide at its base, with domain I
perched on top of the other three domains, which are intimately
connected and probably comprise a single folding unit. The only
contacts between domain I and the rest of the molecule are with
domain II, and these chie¯y involve charged polar and water-
mediated interactions. The nature of the interface is consistent
with the ability of a recombinant N-terminal fragment (residues 1±
254) to be expressed as a soluble folded domain that maintains the
ability to bind PA and enables the translocation of heterologous
fusion proteins into the cytosol15,16.
Domain I consists of a 12-helix bundle that packs against one face
of a mixed four-stranded b-sheet, with a large (30-residue) ordered
loop, L1, between the second and third b-strands forming a ¯ap
over the distal face of the sheet. Although there is no detectable
sequence homology between domains I and IV, the sheet and two
abutting helices can be superposed with a root mean square
difference (RMSD) of 2.6 AÊ . The hallmark metalloprotease motif
HExxH is not conserved in domain I; it is replaced by the sequence
YEIGK, so Zn2+ coordination is not possible. The docking site on
domain I for PA is unknown, but the integrity of the folded domain
seems to be required, because a series of insertion and point mutants
of buried residues in domain I (that presumably disrupt the fold)
abrogate binding of PA and toxicity17,18.
An abrupt turn at the end of the last helix of domain I leads
directly into the ®rst helix of domain II (residues 263±297 and 385±
550). Although sequence-based comparisons failed to yield any
homology, the structural similarity with the catalytic domain of the
B. cereus toxin, VIP2 (Protein Data Bank accession code 1QS2), is
outstanding. Domain II and VIP2 superpose with an RMSD of 3.3 AÊ
and a sequence identity of 15%, as determined by DALI19. VIP2
contains an NAD-binding pocket and conserved residues involved
in NAD binding and catalysis. Domain II lacks these conserved
residues; moreover, a critical glutamic acid that is conserved
throughout the family of ADP ribosylating toxins20 is replaced by
a lysine (K518). We therefore expect that domain II does not have
ADP-ribosylating activity.
Domain III is a small a-helical bundle with a hydrophobic core
(residues 303±382), inserted at a turn between the second and third
helices of domain II. Sequence analysis had revealed the presence of
a 101-residue segment comprising ®ve tandem repeats (residues
282±382), and suggested that repeats 2±5 arose from a duplication
of repeat 1. The crystal structure reveals that repeat 1 actually forms
the second helix-turn element of domain II, whereas repeats 2±5
form the four helix-turn elements of the helical bundle, suggesting a
mechanism of creating a new protein domain by the repeated
replication of a short segment of the parent domain. Domain III
is required for LF activity, because insertion mutagenesis and point
mutations of buried residues in this domain abrogate function17. It
makes limited contact with domain II, but shares a hydrophobic
surface with domain IV. Its location is such that it severely restricts
access to the active site by potential substrates such as the loops of a
globular protein; that is, it contributes towards speci®city for a
¯exible `tail' of a protein substrate. It also contributes sequence
speci®city by making speci®c interactions with the substrate (see
below).
Domain IV (residues 552±776) consists of a nine-helix bundle
packed against a four-stranded b-sheet. Sequence comparisons had
failed to detect any homology with other proteins of known
structure beyond the HExxH motif. Our three-dimensional struc-
ture reveals that the b-sheet and the ®rst six helices can be super-
posed with those of the metalloprotease thermolysin, with an
RMSD of 4.9 AÊ over 131 residues. Large insertions and deletions
occur elsewhere within the loops connecting these elements, so that
the overall shapes of the domains are quite different. In particular, a
Figure 1 Stereo ribbon representation of LF, coloured by domain. The MAPKK-2 substrate
is shown as a red ball-and-stick model, and the Zn2+ ion is labelled. The RMSD (Ca)
between the cubic and monoclinic crystal forms is 1.18 AÊ . The principal differences lie in
the position of the helical bundle of domain IV, which undergoes a rigid body shift of ,2 AÊ
relative to the b-sheet, and a smaller shift of the b-sheet of domain I. The third helical
element of domain III is invisible in the monoclinic crystals, but can be seen in cubic
crystals, albeit with high B-factors. It is possible that this mobile amphipathic helix has a
role in the membrane-inserting properties of LF observed in vitro28. Figure prepared with
MOLSCRIPT, RENDER and RASTER3D29±31.
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large ordered loop (L2) inserted between strands 4b2 and 4b3 of the
sheet partly obscures the active site, packs against domain II, and
provides a buttress for domain III.
A zinc ion (Zn2+) is coordinated tetrahedrally by a water molecule
and three protein side chains (Fig. 3), in an arrangement typical of
the thermolysin family. Two coordinating residues are the histidines
from the HExxH motif (His 686 and His 690) lying on one helix
(4a4), as expected. Our structure reveals that the third coordinating
residue is Glu 735 from helix 4a6. Glu 687 from the HExxH motif
lies 3.5 AÊ from the water molecule, well positioned to act as a general
base to activate the zinc-bound water during catalysis. The hydroxyl
group of a tyrosine residue (Tyr 728) forms a strong hydrogen bond
(O±O distance 2.6 AÊ ) to the water molecule, on the opposite side of
Glu 687, and probably functions as a general acid to protonate the
amine leaving group.
A broad deep groove, 40 AÊ long, is contiguous with the active site
centre; it is created by the vestigial NAD-binding pocket of domain
II and by the interface between domains II, III and IV. The groove
has in general a negative potential, containing clusters of glutamic
acid/aspartic acid, as well as glutamine/asparagine residues. We
introduced peptides corresponding to the N-terminal 16 residues of
MAPKK-2 into crystals of LF. In the absence of Zn2+, we observed
continuous electron density that can accommodate the entire 16-
residue peptide, extending from domain II through the catalytic
centre and ending at the distal end of domain IV (Fig. 4). We
observed similar peptide density in the presence of Zn2+ in peptide-
Figure 2 Sequence of LF, coloured as in Fig. 1, with secondary structure indicated. The
N-terminal 26 residues are invisible in our electron density maps, and we presume that
they are disordered. All other residues are ordered in at least one crystal form. The ®ve
sequence repeats are indicated R1±R5. The zinc-coordinating residues are highlighted in
red. The sequence of domain I is homologous to the PA-binding domain of oedema factor,
and its three-dimensional structure will be similar. For domain II, secondary structure
nomenclature matches that of the N-terminal domain of VIP2.
Figure 3 Stereo representation of the active site centre of LF. Zinc-coordinating residues
are shown in ball-and-stick representation with the Zn2+ ion in magenta and the zinc-
bound water labelled v. Zinc±ligand bond distances are 2.1 6 0.1 AÊ (mean 6 s.d.). The
molecular surface de®ning the S1 substrate-binding pocket is indicated. Part of the
MAPKK-2 model derived crystallographically is shown in grey. A hypothetical model of the
productive complex is in yellow, blue and red. A rotation about the Lys 6±Pro 7 main chain
would bring Pro 10 into the S1 pocket, positioning the scissile bond close to the zinc-
bound water, as indicated. The equivalent residue to Pro 10 in MAPKK-3 is Arg 26, which
has a side chain that is also modelled in the S1 pocket, where it could form a salt bridge
with the buried Glu 739. A hydrophobic residue (Leu 9 in MAPKK-2) is favoured at the P19
position, and our model suggests that it can interact with Val 675, at the top of the S1
pocket. Figs 3 and 4 were prepared with SPOCK32.
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soaked crystals of a mutant (E687C) that lacks catalytic activity but
that binds Zn2+ normally10 (data not shown). A brief (5 min) soak of
the wild-type complex in Zn2+ led to the disappearance of most of
the peptide electron density and a strong peak at the Zn2+ position,
consistent with activation of the proteolytic machinery. We built a
peptide model that shows convincing agreement with the electron
density lying in the direction expected for a thermolysin family
member. Residues 1±3 sit wholly within the groove of domain II,
surrounded by a cluster of asparagine and glutamine residues.
Residues 4±10 are sandwiched between domains III and IV. A
strongly acidic region of the protein surface rationalizes the pref-
erence for basic residues in the MAPKK substrates located 3±6
residues upstream of the cleavage site6. Arg 4 makes speci®c hydro-
gen bonds with domain III, and Pro 7 points towards an acidic
cavity large enough to accommodate the lysine or arginine side
chains found in the equivalent positions in MAPKK-1 and -3.
Beyond Pro 7, the peptide makes fewer speci®c contacts.
This is, to our knowledge, the ®rst structural example of a
protease in complex with its uncleaved natural substrate. The closest
main-chain approach to the Zn2+ ion is the scissile bond following
Pro 10. However, it is about 6 AÊ from the zinc-bound water,
suggesting that we have captured a `pre-cleavage' complex. Such
complexes have been predicted on the basis of kinetic data21 but
have not previously been observed crystallographically, presumably
because, for the shorter recognition sequences of typical proteases,
this binding mode is much weaker. Modelling studies show that a
rotation about a main-chain dihedral angle at Lys 6 would allow
Pro 10 to swing down into the S1 speci®city pocket to generate the
productive cleavage complex (Fig. 3). This conformational change
would not disturb the speci®c interactions between LF and the N-
terminal half of the MAPKK tail. The productive conformation
requires an abrupt 908 turn in the peptide chain (favoured by a
proline residue) at the P1 position, which would explain why a
proline-to-alanine point mutant is not cleaved ef®ciently4. The S1
pocket is very pronouncedÐhydrophobic at its neck and acidic at
its baseÐappropriate to ®t the arginine or lysine side chains found
at the P1 position in other MAPKK members6. Although the length
of the pocket ®ts the N termini of MAPKK-1 and -2 very well, the
pocket is not closed at its N-terminal end, so longer tails, such as
those of other MAPKK members, could simply protrude beyond the
pocket. At its C terminus, where the globular domain of MAPKK
begins, the peptide just protrudes from between domains III and IV.
These surfaces may thus provide additional docking sites for other
domains on the MAPKK, because fragments of MAPKK-1 lacking
the N-terminal tail also bind to LF in a two-hybrid screen5.
The atomic resolution structure of LF described here demon-
strates that the remarkable speci®city for MAPKK family members
arises in large part from the existence of an extended substrate-
binding pocket created by gene duplication and fusion, which
recognizes both the structural and sequence properties of its
substrate. This information can be used in the design of therapeutic
agents that would block the activity of LF in vivo. Our structure may
also allow the design of mutant LF molecules with altered speci®-
cities for different members of the MAPKK family and hence
improved anti-tumour properties, for example. M
Methods
Structure of the monoclinic crystal form
LF was puri®ed as described elsewhere22. A mixture of cubic and monoclinic crystals were
grown from 13 mg ml-1 LF, 1.7±1.9 M ammonium sulphate, 0.2 M Tris buffer at pH 7.5±
8.0, by the hanging-drop vapour diffusion method. The predominant crystal form is cubic
(I4132 a = 331 AÊ ); these crystals diffract to 3.8 AÊ resolution. Monoclinic crystals (P21 a =
96.2 AÊ , b = 137.5 AÊ , c = 98.6 AÊ , b = 98.48) were selectively obtained by macroseeding, and
these diffract to 2.2 AÊ resolution. Derivatives of the monoclinic form were prepared by
transferring the crystals to a stabilization buffer containing 2 M lithium sulphate, 200 mM
Tris at pH 7.5, and either 50 mM trimethyl-lead acetate for 8 h or 15 mM potassium
hexaiodoplatinate for 45 min. Native data were collected on station 9.6 at the Synchrotron
Radiation Source (SRS) (Daresbury, UK); a platinum derivative data set was collected on
an R-Axis IV image plate, and a multiple (three)-wavelength anomalous diffraction
(MAD) data set from the lead derivative was collected on BM14 at the European
Synchrotron Radiation Facility (ESRF) (Grenoble). All data were collected at 100 K after
transfer to a cryoprotectant containing 25% glycerol. Data were indexed, integrated and
scaled with the HKL package23 and heavy-atom sites were identi®ed and re®ned with
FHSCAL, FFT and MLPHARE from the CCP4 suite24 or with the program SOLVE25. The
®nal ®gure of merit was 0.51 at 3.2 AÊ . The rotational component of a two-fold
noncrystallographic symmetry (NCS) axis was identi®ed with POLARRFN24 and the
translation with GETAX24. Model building was carried out by the graphics program
TURBO-FRODO26 and re®ned with CNS27 using all data and a bulk solvent correction. A
monomer mask was identi®ed in a map solvent ¯attened with DM, allowing strict NCS
constraints to be used in model building and map calculation. The R-factor converged at
around 30%; NCS constraints were released and a further cycle of re®nement resulted in a
drop in the Rfree of almost 3%. Multiple cycles of re®nement, rebuilding and addition of
water molecules reduced the R-factors to ®nal values of 0.225 (Rwork) and 0.26 (Rfree) at
2.2 AÊ . The resulting model fell within, or exceeded, the limits of all the quality criteria of
the program PROCHECK24. The ®nal model contains 1,497 residues (residues 27±773 of
molecule A and 27±776 of molecule B), 934 water molecules, 2 sulphate ions and 2 zinc
ions. A table of crystallographic statistics is provided in Supplementary Information.
Structure of the cubic crystal form
We solved cubic structure by molecular replacement with MOLREP24, using the re®ned
model of the P21 crystal form converted to polyalanine as a search probe. The cubic
crystals contained one molecule in the asymmetric unit and 86% solvent. The initial
solution (Rfree = 0.49) underwent preliminary re®nement using rigid body minimization
and simulated annealing procedures in CNS27 to Rfree = 0.38. Owing to the limited
resolution (3.8 AÊ ) and the rapid fall-off in diffraction intensity, the data were sharpened
with an overall B-factor of 50 AÊ 2 (on I), to increase the weight of the high-resolution terms.
The resulting difference and omit maps used for rebuilding revealed higher resolution
features, such as improved side-chain density.
Structure of peptide complex
The monoclinic crystals cracked on exposure to MAPKK peptides, so the cubic form was
used for substrate binding studies. The highest peptide occupancy was achieved with a
5-min room-temperature soak of crystals in 10 mM MAPKK-2 peptide (MLARRKPVLP
ALTINP) in cryoprotectant in the absence of zinc. A 2Fo - Fc map revealed an additional
elongated stretch of electron density in the active site crevice. A peptide model containing
the MAPKK-2 sequence was built and subjected to further cycles of re®nement and
rebuilding with the programs REFMAC524 and TURBO-FRODO26. Periodically and for
®nal maps, model bias was minimized by excluding the peptide from the phasing and
carrying out a cycle of re®nement (`simulated annealing omit map'27). Assuming an
occupancy of 0.7, the peptide main chain B-factors re®ne to values similar to those of the
protein. The ®nal model for the cubic data has been re®ned to Rfree = 0.316 (0.402 in the
3.9±4.0 AÊ shell), Rwork = 0.295.
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